close
References
  1. Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831-846.
  2. Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet. 2021;14:11-25.
  3. Gabanella F, Carissimi C, Usiello A, Pellizzoni L. The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation. Hum Mol Genet. 2005;14(23):3629-3642.
  4. Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51(2):157-167.
  5. Mercuri E, Finkel RS, Muntoni F, et al; SMA Care Group. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103-115.
  6. Prior TW, Leach ME, Finanger E. Spinal muscular atrophy. February 24, 2000. Last updated December 3, 2020. In: Adam MP, Arding HH, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington; 1993-2022.
  7. Washington University. Spinal muscular atrophy (5q). Last updated August 28, 2019. Accessed February 9, 2022. https://neuromuscular.wustl.edu/pathol/sma.htm
  8. Sumner CJ, Crawford TO. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest. 2018;128(8):3219-3227.
  9. Cure SMA. What is newborn screening? Accessed February 9, 2022. https://www.curesma.org/newborn-screening-for-sma
  10. Finkel RS, Mercuri E, Meyer OH, et al; SMA Care Group. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197-207.
  11. Chen TH. New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand? Int J Mol Sci. 2020;21(9):3297.
  12. Cure SMA. Cure SMA immunizations recommendations during flu season and amidst the COVID-19 pandemic. October 28, 2020. Accessed February 12, 2022. https://www.curesma.org/flu-immunization-recommendations
  13. Cure SMA. Quality of life. Accessed February 11, 2022. https://www.curesma.org/quality-of-life
  14. Klotz J, Tesi Rocha C, Dunaway Young S, et al. Advances in the therapy of spinal muscular atrophy. J Pediatr. 2021;236:13-20.e1.
  15. SPINRAZA (nusinersen) injection. Prescribing information. Biogen; 2020.
  16. Finkel RS, Mercuri E, Darras BT, et al; ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-1732.
  17. Mercuri E, Darras BT, Chiriboga CA, et al; CHERISH Study Group. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625-635.
  18. Hagenacker T, Wurster CD, Günther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317-325.
  19. Duong T, Wolford C, McDermott MP, et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract. 2021;11(3):e317-e327.
  20. Vlodavets D, Darras BT, Masson R, et al. FIREFISH part 2: 24-month efficacy and safety of risdiplam in infants with type 1 SMA. Presented at 16th International Congress on Neuromuscular Diseases (ICNMD 2021). Virtual; May 2021.
  21. Roche. Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with SMA. June 12, 2020.
  22. EVRYSDI (risdiplam). Prescribing information. Genentech, Inc., a Member of the Roche Group; 2021.
  23. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-1722.
  24. Servais L, De Vivo D, Kirschner J, et al. Routine practices in use of onasemnogene abeparvovec (OA) in older patients with spinal muscular atrophy (SMA): early findings from RESTORE. Neuromuscul Disord. 2021;31(suppl 1):S138.
  25. ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension. Novartis Gene Therapies, Inc.; 2021.
  26. Crawford TO, Day JW, Darras BT, et al. Apitegromab in spinal muscular atrophy (SMA): an analysis of multiple efficacy endpoints in the TOPAZ trial. Presented at World Muscle Society Meeting 2021. Virtual; September 2021.
  27. Messina S, Sframeli M. New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med. 2020;9(7):2222.
  28. Chaytow H, Faller KME, Huang YT, Gillingwater TH. Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med. 2021;2(7):100346.
  29. Rudnicki SA, Andrews JA, Duong T, et al. Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study. Neurotherapeutics. 2021;18(2):1127-1136.
  30. Clinicaltrials.gov. Study of nusinersen (BIIB058) in participants with spinal muscular atrophy (DEVOTE). Last updated February 24, 2022. Accessed April 20, 2022. https://clinicaltrials.gov/ct2/show/NCT04089566
  31. Clinicaltrials.gov. A study of nusinersen among participants with spinal muscular atrophy who receive onasemnogene abeparvovec (RESPOND). Last updated April 11, 2022. Accessed April 20, 2022. https://clinicaltrials.gov/ct2/show/NCT04488133
  32. Novartis. Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal phase 3 study of intrathecal OAV-101 in older patients with SMA. August 3, 2021.
  33. Novartis. Novartis to initiate SMART phase 3b global study of zolgensma in children up to 21 kg, building on real-world experience. April 23, 2021.
  34. Mercuri E, Finkel R, Day J, et al. Part A results from the ongoing DEVOTE study to investigate higher nusinersen dosing in SMA. Presented at World Muscle Society Meeting 2021. Virtual; September 2021.
  35. Clinicaltrials.gov. Extension study of nusinersen (BIIB058) in participants with spinal muscular atrophy who previously participated in a study with nusinersen (ONWARD). Last updated January 24, 2022. Accessed March 30, 2022. https://clinicaltrials.gov/ct2/show/NCT04729907
  36. Proud C, Parsons J, Brandsema J, et al. Nusinersen in children with spinal muscular atrophy (SMA) who received onasemnogene abeparvovec: design of the phase 4 open-label RESPOND study. Presented at World Muscle Society Meeting 2021. Virtual; September 2021.
  37. Biogen. Biogen announces first patient treated in RESPOND study evaluating benefit of SPINRAZA® (nusinersen) in patients treated with zolgensma (onasemnogene abeparvovec). January 8, 2021.
  38. Krosschell K, Dunaway Young S, Cruz R, et al. Best practices for physical therapists & clinical evaluators in spinal muscular atrophy (SMA): recommendations to support the effective conduct of clinical trials in SMA. 2021 Families of Spinal Muscular Atrophy d/b/a Cure SMA. Accessed February 10, 2022. https://www.curesma.org/wp-content/uploads/2021/09/Clinical-Evaluators-Best-Practices-13-August-2021.pdf
  39. Kolb SJ, Coffey CS, Yankey JW, et al; NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883-891.
  40. De Vivo DC, Bertini E, Swoboda KJ, et al; NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842-856.
  41. Baranello G, Darras BT, Day JW, et al; FIREFISH Working Group. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915-923.
  42. O'Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord. 2007;17(9-10):693-697.
  43. Glanzman AM, O'Hagen JM, McDermott MP, et al; Pediatric Neuromuscular Clinical Research Network for Spinal Muscular Atrophy (PNCR); Muscle Study Group (MSG). Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol. 2011;26(12):1499-1507.
  44. Mercuri E, Baranello G, Kirschner J, et al. Update from SUNFISH part 1: safety, tolerability, and PK/PD from the dose-finding study, including exploratory efficacy data in patients with type 2 or 3 spinal muscular atrophy (SMA) treated with risdiplam (RG7916). Presented at American Academy of Neurology 2019 Annual Meeting. Philadelphia, PA; May 4-10, 2019.
  45. Mazzone E, Bianco F, Martinelli D, et al. Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord. 2011;21(6):406-412.
  46. Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55(6):869-874.
  47. Pera MC, Coratti G, Mazzone ES, et al; iSMAC Consortium Group. Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve. 2019;59(4):426-430.
  48. Day J. Update of CY-5021: a phase 2 clinical trial of reldesemtiv, a fast skeletal muscle troponin activator (FSTA), for the potential treatment of spinal muscular atrophy. Presented at International Cure SMA Research Meeting. Orlando, FL; June 2018.
  49. Montes J, Dunaway Young S, Mazzone ES, et al; CS2 and CS12 Study Groups. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve. 2019;60(4):409-414.
  50. Folio MR, Fewell RR. Peabody Developmental Motor Scales Examiner’s Manual, 2nd ed. Pro-Ed; 2000.
  51. Murrell DV, Crawford CA, Jackson CT, Lotze TE, Wiemann CM. Identifying opportunities to provide family-centered care for families with children with type 1 spinal muscular atrophy. J Pediatr Nurs. 2018;43:111-119.
  52. Wolfe AD, Frierdich SA, Wish J, Kilgore-Carlin J, Plotkin JA, Hoover-Regan M. Sharing life-altering information: development of pediatric hospital guidelines and team training. J Palliat Med. 2014;17(9):1011-1018.
  53. Hill C, Knafl KA, Santacroce SJ. Family-centered care from the perspective of parents of children cared for in a pediatric intensive care unit: an integrative review. J Pediatr Nurs. 2018;41:22-33.
  54. Biogen. Starting Spinraza/how to start. Accessed February 10, 2022. https://www.spinraza-hcp.com/en_us/home/starting-spinraza/how-to-start.html
  55. Novartis Gene Therapies, Inc. The OneGene program. Last updated November 2021. Accessed February 10, 2022. https://www.zolgensma.com/onegene-program
  56. Genentech USA, Inc. Evrysdi start form. Accessed February 10, 2022. https://www.genentech-access.com/content/dam/gene/accesssolutions/pdfs/start-form/Evrysdi-Start-Form.pdf
  57. Monsivais D, Reynolds A. Developing and evaluating patient education materials. J Contin Educ Nurs. 2003;34(4):172-176.
  58. Willems J, Farin-Glattacker E, Langer T. Evaluation of a case management to support families with children diagnosed with spinal muscular atrophy—protocol of a controlled mixed-methods study. Front Pediatr. 2021;9:614512.
  59. Pasquini TLS, Goff SL, Whitehill JM. Navigating the U.S. health insurance landscape for children with rare diseases: a qualitative study of parents' experiences. Orphanet J Rare Dis. 2021;16(1):313.
  60. Cure SMA. Choice and connection to care: a health insurance roadmap for people living with spinal muscular atrophy (SMA) and their caregivers. 2017. https://www.curesma.org/cure-sma-releases-care-series-booklet-on-insurance
  61. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. American Psychiatric Association; 2013.